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Abstract 41 
 Four specimens of the olive sea snake, Aipysurus laevis, were collected off the 42 
coast of Western Australia, and the venom proteome was characterized and 43 
quantitatively estimated by RP-HPLC, SDS-PAGE, and MALDI-TOF-TOF analyses. A. 44 
laevis venom is remarkably simple and consists of phospholipases A2 (71.2%), three-45 
finger toxins (3FTx; 25.3%), cysteine-rich secretory proteins (CRISP; 2.5%), and traces 46 
of a complement control module protein (CCM; 0.2%). Using a Toxicity Score, the 47 
most lethal components were determined to be short neurotoxins. Whole venom had an 48 
intravenous LD50 of 0.07 mg/kg in mice and showed a high phospholipase A2 activity, 49 
but no proteinase activity in vitro. Preclinical assessment of neutralization and ELISA 50 
immunoprofiling showed that BioCSL Sea Snake Antivenom was effective in cross-51 
neutralizing A. laevis venom with an ED50 of 821 μg  venom  per  mL  antivenom,  with  a  52 
binding preference towards short neurotoxins, due to the high degree of conservation 53 
between short neurotoxins from A. laevis and Enhydrina schistosa venom. Our results 54 
point towards the possibility of developing recombinant antibodies or synthetic 55 
inhibitors against A. laevis venom due to its simplicity. 56 
(176 words) 57 
58 
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1. Introduction 59 
The viviparous sea snakes are a diverse clade of more than 60 species that are 60 
phylogenetically nested within the front-fanged Australo-Melanesian terrestrial elapids 61 
(Hydrophiinae) (Rasmussen et al., 2011). They are highly aquatic and occupy most 62 
shallow-marine habitats throughout the tropical and subtropical Indo-West Pacific, yet 63 
are estimated to share a common ancestor dated at only 6–8 million years ago (Sanders 64 
et al., 2008; Lukoschek et al., 2012). The amphibious sea kraits (Hydrophiinae: 65 
Laticauda) represent an independently aquatic and earlier diverging lineage that is the 66 
sister to terrestrial and viviparous marine hydrophiines (Keogh, 1998; Scanlon and Lee, 67 
2004; Sanders et al., 2008). Two major clades are recognised within the viviparous 68 
marine group:   An   ‘Aipysurus’ lineage comprising ten species found primarily in the 69 
Australo-Papuan region,   and   a   ‘Hydrophis’   lineage   containing at least 50 species 70 
distributed throughout the Indo-West Pacific (Rasmussen et al., 2011). 71 
 In the Aipysurus group, the olive sea snake, Aipysurus laevis, has a large 72 
muscular head and is the most robustly built and longest species recorded, reaching 73 
more than 170 cm in total length (Smith, 1926; Cogger, 1975). A. laevis has been 74 
recorded from Aru Archipelago and Kai Islands (Indonesia) in the west and from the 75 
northern coast of Australia and southern coast of New Guinea (Timor Sea and Arafura 76 
Sea) to New Caledonia in the east (Coral Sea) (Cogger, 1975; Ineich and Rasmussen, 77 
1997; Sanders et al., 2014). A. laevis is found in shallow marine habitats – coral reefs as 78 
well as sandy, rocky, and mud-bottom habitats, and is often one of the most abundant 79 
species throughout its range (Cogger, 1975; Lukoschek et al., 2007; Sanders et al., 80 
2014). It hunts primarily in crevices on the sea floor, and the following fish families 81 
have been found as prey items in A. laevis: Acanthuridae, Apogonidae, Carangidae, 82 
Clupeidae, Engraulidae, Labridae, Lutjanidae, Pempheridae, Pomacentridae, Scaridae, 83 
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Scorpaenidae and Serranidae (McCosker, 1975; Voris and Voris, 1983). Fish eggs, 84 
crabs, shrimp and pelecypod (Limidae) have also been found in stomach content 85 
(McCosker, 1975; Voris and Voris, 1983). 86 
 During mating season A. laevis is more prone to defensive attacks than at other 87 
times of the year (Heatwole, 1975). However, normally A. laevis will ignore a diver 88 
even if the diver approaches quite close (Heatwole, 1975). A. laevis has up to at least 5 89 
mm long fangs and the venom is known for being extremely toxic (Limpus, 1978; 90 
Minton, 1983; Mackessy and Tu, 1993; Greer, 1997). A. laevis is commonly caught as 91 
by-catch, and commercial trawler fishers and recreational fishers handling nets are 92 
therefore the typical bite victims of A. laevis. 93 
The venoms of sea snakes, typically containing D-neurotoxins and 94 
phospholipases A2 (PLA2s), are known to be generally more potent than the venoms 95 
from terrestrial snakes in terms of lethality (Minton, 1983; Takasaki, 1998). In contrast 96 
to the latter, however, only few studies have been focused on determining the 97 
comprehensive composition of sea snake venoms by means of proteomic analyses, i.e. 98 
venomics. The venom of A. laevis has been shown to be neurotoxic, nephrotoxic, and 99 
myotoxic in mice, causing acute renal tubular degeneration, proliferative 100 
glomerulonephritis, local muscle degeneration, necrosis, enlarged spleen, inflammation, 101 
and lymphadenopathy (Zimmerman et al., 1992a, 1992c; Ryan and Yong, 1997, 2002). 102 
Regarding the venom components of A. laevis, a total of four short-chain neurotoxin 103 
isoforms with minor amino acid sequence variations (P19958, P19959, P19960, and 104 
P32879) and one PLA2 (P08872) have been fully sequenced (Maeda and Nobuo, 1976; 105 
Ducancel et al., 1988, 1990). The short D-neurotoxins display a high affinity towards 106 
the acetylcholine receptor (Ishikawa et al., 1977), which is in agreement with the very 107 
low LD50 observed for the whole venom (Tamiya, 1973; Maeda and Nobuo, 1976). 108 
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Toxicity of the venom has additionally been tested in different fish species, showing 109 
variations in responses (Berman, 1983; Zimmerman et al., 1990, 1992a, 1992c). It has 110 
been suggested that several components of the venom may act in a synergistic manner 111 
to potentiate toxic effects (Ryan and Yong, 1997). Finally, antivenoms raised against 112 
tiger snake (Notechis scutatus) or common sea snake (Enhydrina schistosa) venoms 113 
have been shown to have some cross-reactivity towards the venom of A. laevis, 114 
although the efficacies of these antivenoms are lower than against the venoms of 115 
homologous species (Baxter and Gallichio, 1974). 116 
 Aiming to further develop understanding of sea snake venoms and to expand 117 
knowledge of venom intra-species variability, this study presents the proteomic analysis 118 
of the venom of A. laevis, together with an assessment of variability in three different 119 
specimens, and of toxicity of all its main protein components in mice. In addition, the 120 
ability to cross-recognize and neutralize A. laevis venom was evaluated for two 121 
antivenoms against coral snakes and sea snakes. 122 
 123 
2. Materials and Methods 124 
2.1 Snake venom 125 
 Aipysurus laevis venom was obtained from four specimens   (“Mifisto”,  126 
“Medusa”,   “His”,   and   “Nessi”)   kept   at   the   National Aquarium, Den Blå Planet, 127 
Denmark. All specimens were collected at night by Kate L. Sanders from a boat using 128 
spotlights and dip nets. The boat was operating at shallow water close to Broome, 129 
Australia. The venom, collected in the National Aquarium of Denmark, was 130 
immediately frozen, lyophilized, and kept at -20 qC. In order to assess individual 131 
variability, a small sample of venom from each snake was kept separated, while the 132 
remaining material was pooled. 133 
 7 
 134 
2.2 Venom separation by reverse-phase HPLC and SDS-PAGE  135 
 The pooled venom of A. laevis was fractionated by sequential RP-HPLC and 136 
SDS-PAGE separation steps, following the ‘snake   venomics’   analytical   strategy  137 
(Calvete, 2011) under conditions described previously (Lomonte et al., 2014). Venom 138 
load for the RP-HPLC step on C18 (4.6 x 250 mm column, 5 Pm particle diameter; 139 
Teknokroma) was 2 mg. Protein fractions were monitored at 215 nm, manually 140 
collected, dried by vacuum centrifugation, and electrophoretically separated under 141 
reducing conditions. Resulting bands were stained with colloidal Coomassie blue G-142 
250, and digitally recorded on a ChemiDoc® imager using ImageLab® software (Bio-143 
Rad). 144 
 145 
2.3 Protein identification by tandem mass spectrometry of tryptic peptides 146 
 Protein bands were excised from gels, destained with 50% acetonitrile in 25 mM 147 
ammonium bicarbonate, and then subjected to reduction (10 mM dithiothreitol), 148 
alkylation (50 mM iodoacetamide), and overnight in-gel digestion with sequencing 149 
grade trypsin (Sigma), in 50 mM ammonium bicarbonate at 37°C. The resulting tryptic 150 
peptides were extracted with 50% acetonitrile containing 1% trifluoroacetic acid (TFA), 151 
and analyzed by MALDI-TOF-TOF on an AB4800-Plus Proteomics Analyzer (Applied 152 
Biosystems), under conditions previously described (Lomonte et al., 2014). In each run, 153 
CalMix® standards (ABSciex) spotted onto the same plate were used as external 154 
calibrants. Resulting spectra were searched against the UniProt/SwissProt database 155 
using ProteinPilot® v.4 and the Paragon® algorithm (ABSciex) for protein identification 156 
at  ≥  95%  score confidence, or manually interpreted. Few peptide sequences with lower 157 
confidence scores were manually searched using BLAST (http://blast.ncbi.nlm.nih.gov) 158 
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for protein similarity and assignment to protein families. 159 
 160 
2.4 Relative protein abundance estimations 161 
 Areas of the RP-HPLC chromatographic peaks at 215 nm were integrated using 162 
ChemStation® (Agilent) in order to estimate relative protein abundances (Calvete, 163 
2011). For peaks containing several electrophoretic bands, percentage distributions were 164 
assigned by densitometry, using ImageLab® (Bio-Rad). 165 
 166 
2.5 Phospholipase A2 and proteolytic enzyme activities 167 
Enzymatic activities of A. laevis venom were tested comparatively with samples 168 
obtained from other elapid snakes (Dendroaspis polylepis, Naja kaouthia; obtained 169 
from Latoxan, France; and Micrurus nigrocinctus, obtained from Instituto Clodomiro 170 
Picado) or the viperid Bothrops asper (Instituto Clodomiro Picado). PLA2 activity was 171 
assayed on the chromogenic 4-nitro-3-octanoyloxybenzoic acid (NOBA) synthetic 172 
substrate, as described (Lomonte et al., 2015). Venoms (20 Pg,  dissolved   in  25  μL  of    173 
10 mM Tris, 10 mM CaCl2, 0.1 M NaCl, pH 8.0, buffer) were  mixed  with  200  μL  of  the 174 
same buffer and  25  μL  of  NOBA  to  achieve  a  final  substrate  concentration  of  0.32  mM.  175 
Plates were incubated for 60 min at 37 °C, and absorbance was recorded at 405 nm in a 176 
microplate reader. Proteolytic activity was determined on azocasein, according to Wang 177 
et al. (2004). Venoms (40  μg, dissolved in 50 mM Tris–HCl, 0.15 M NaCl, 5 mM CaCl2 178 
buffer, pH 8.0)  were  added  to  100  μL  of  azocasein  (10  mg/mL in the same buffer), and 179 
incubated  for  90  min  at  37  °C.  The  reaction  was  stopped  by  addition  of  200  μL  of  5%  180 
trichloroacetic acid, and after centrifugation (5 min, 13,000 rpm),   150   μL   of 181 
supernatants were mixed with 100  μL  of  0.5  M  NaOH,  and  absorbance  was recorded at 182 
450 nm. All samples in these assays were run in triplicate wells, and controls of solvents 183 
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without venoms were included. 184 
 185 
2.7 Lethality screening 186 
 Lethality assays were conducted in CD-1 mice, supplied by Instituto Clodomiro 187 
Picado, following protocols approved by the Institutional Committee for the Use and 188 
Care of Animals (CICUA), University of Costa Rica. The lethality of the whole venom 189 
and fractions or isolated toxins was tested by intravenous (i.v.) injection in groups of 190 
four mice (18–20 g body weight). Various amounts of venom or fractions/toxins were 191 
dissolved in phosphate-buffered saline (PBS; 0.12 M NaCl, 0.04 M sodium phosphate 192 
buffer, pH 7.2), and injected in the caudal vein, using a volume of 100 µL. Deaths 193 
occurring within 24 h were recorded, and the LD50 values were calculated by probits 194 
(Finney, 1971), using the BioStat® software (AnalySoft). 195 
The toxicity of venom fractions was initially screened by selecting a dose based on 196 
fraction abundance. The dose was selected to assess whether the fraction would score 197 
above or below 1 according to the Toxicity Score defined by Laustsen et al. (2015a) as 198 
the toxin abundance (%) divided by its LD50. Fractions that were not lethal at this dose 199 
(yielding a Toxicity Score <1) were considered as having insignificant toxicity, whereas 200 
fractions, which did kill mice at this level, were further evaluated, and LD50 values were 201 
determined for them. 202 
 203 
2.8 Myotoxicity of phospholipases A2 204 
 A pool of all the PLA2 fractions was prepared, and doses of 30 µg, dissolved in 205 
50 µL PBS, were injected intramuscularly, either in the right gastrocnemius, the thigh or 206 
the soleus, to groups of five mice (18-20 g). In another experiment, mice received 30 µg 207 
of the PLA2 fractions in the soleus muscle. Injection of PBS was used for the control 208 
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group. Blood was collected after 3 h from the tip of the tail into heparinized capillaries. 209 
Plasma creatine kinase (CK) activity was determined using an UV kinetic assay (CK-210 
Nac®, Analyticon). After blood collection, mice were sacrificed by CO2 inhalation and a 211 
sample of muscles were obtained and immediately fixed in 10% formalin solution. After 212 
routine processing, tissues were embedded in paraffin, sectioned, and stained with 213 
hematoxylin-eosin for histological observation. In addition, in order to assess the acidic 214 
or basic nature of the various PLA2s of the venom, chromatographic peaks 9-18 were 215 
analyzed by zone electrophoresis under native conditions, using a 1% agarose gel 216 
dissolved in 0.1 M Tris, 0.3 M glycine, pH 8.6 buffer. The gel was run at 75 V for 90 217 
min, and protein migration was detected by Coomassie R-250 staining.  218 
  219 
2.9 Antivenom neutralization studies 220 
 Two antivenoms were used: (a) BioCSL Sea Snake Antivenom, manufactured 221 
by BioCSL Limited (Melbourne, Victoria, Australia) (batch 054908201; expiry date: 222 
04/2015);  (b) Monospecific Micrurus nigrocinctus Anticoral Antivenom from Instituto 223 
Clodomiro Picado (batch 5310713ACLQ, expiry date 07/2016), for comparison. 224 
Mixtures containing a fixed amount of venom and several dilutions of antivenoms were 225 
prepared using PBS as diluent, and incubated at 37 ºC for 30 min. Controls included 226 
venom incubated with PBS instead of antivenom. Aliquots of 100 µL of the solutions, 227 
containing 4×LD50 of venom (11.2 µg/mouse) were then injected i.v. into groups of four 228 
mice (18-20 g). Deaths occurring within 24 h were recorded for assessing the 229 
neutralizing capacity of antivenoms. Neutralization was expressed as the Median 230 
Effective Dose (ED50) of antivenom, defined as the ratio Pg venom/mL antivenom at 231 
which 50% of the injected mice were protected. ED50s were estimated by probits, as 232 
described in Section 2.7.  233 
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 234 
2.10 Antivenom immunoprofiling by ELISA 235 
 Wells in MaxiSorp plates (NUNC, Roskilde, Denmark) were coated overnight 236 
with 0.6 μg of each HPLC venom fraction, dissolved in 100 μL PBS. Then, wells were 237 
blocked by adding 100 μL   PBS   containing   2%   (w:v)   bovine   serum   albumin   (BSA,  238 
Sigma) at room temperature for 1 h, and washed five times with PBS. A dilution of each 239 
antivenom in PBS containing 2% BSA was prepared such that the protein concentration 240 
was   86   μg/mL   (as  measured   by   their   absorbance   at   280   nm   on   a  NanoDrop® 2000c 241 
instrument, Thermo Scientific), and 100  μL  were  added  to  the  wells for 2 h. After five 242 
washings with PBS, 100 µL of a 1:2000 dilution of rabbit anti-horse IgG (whole 243 
molecule)-alkaline phosphatase conjugated antibodies (Sigma A6063, in PBS, 2% BSA) 244 
was added to each well for 2 h, and then washed five times with FALC buffer (0.05 M 245 
Tris, 0.15 M NaCl, 20 PM ZnCl2, 1 mM MgCl2, pH 7.4). Color was developed by 246 
adding 100 µL of p-nitrophenyl phosphate (1 mg/mL in 9.7% v/v diethanolamine 247 
buffer, pH 9.8), and the absorbances at 405 nm were recorded at several time intervals 248 
in a microplate reader (Multiskan FC, Thermo Scientific). 249 
 250 
 251 
3.0 Results and Discussion 252 
3.1 Venomics 253 
 A detailed proteomics characterization was performed on the pooled venom 254 
from A. laevis. From 20 fractions resolved by RP-HPLC, 35 peptidic bands were 255 
obtained after SDS-PAGE separation (Fig.1). By in-gel digestion and MALDI-TOF-256 
TOF analysis, 99.2% of the protein bands could be assigned to toxin families. As shown 257 
in Fig.2, the predominant family of proteins in this venom corresponds to PLA2s 258 
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(71.2%), followed by a significant proportion of three-finger toxins (3FTx; 25.3%). A 259 
small amount of cysteine-rich secretory proteins (CRISP; 2.5%) and traces of a 260 
complement control module protein (CCM; 0.2%) were also detected. These results 261 
highlight the simple protein family composition of A. laevis venome, which essentially 262 
relies on a relatively small group of PLA2 and 3FTx isoforms to exert its trophic role. 263 
Also, these findings are in agreement with the trend emerging from recent proteomic 264 
studies on sea snake venoms, which have revealed that their venoms are much simpler 265 
than their terrestrial elapid counterparts in terms of the number of dominant protein 266 
families and diversification of isoforms, typically within the PLA2 and 3FTx families 267 
(Fry et al., 2003; Li et al., 2005). Thus far, sea snake venom proteomes have been 268 
deciphered for Hydrophis cyanocinctus (Calvete et al., 2012) and Pelamis platura 269 
(Lomonte et al., 2014). Similar to these, A. laevis venom contains few toxin families. 270 
However, in contrast to the venoms of P. platura and H. cyanocinctus, where the main 271 
toxin families are three-finger toxins (50% and 81% of all venom proteins, respectively) 272 
followed by PLA2s (33% and 19% of all venom proteins, respectively), A. laevis venom 273 
displays the opposite relative venom composition, being dominated by PLA2s (71.2%) 274 
followed by 3FTxs (25.3%). Furthermore, whereas the three-finger toxins of A. laevis 275 
venom are all short neurotoxins, P. platura and H. cyanocinctus venoms contain both 276 
short and long neurotoxins. The current findings on A. laevis venom composition differ 277 
from a previous study, where three of the short neurotoxins were reported to represent 278 
22%, 33%, and 21% of the venom (76% altogether), respectively (Maeda and Tamiya, 279 
1976). The reasons behind these discrepant results are difficult to determine, although 280 
they may reflect possible intraspecies differences in venom composition in specimens 281 
collected in different geographical locations: Maeda and Tamiya (1976) used A. laevis 282 
collected from Ashmore Reef, which is separated from our collection localities near 283 
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Broome by more than 600 km of mostly unsuitable (deep water) habitat. Potentially, the 284 
observed differences could also be explained by interspecific hybridization, which has 285 
previously been observed for A. laevis and closely related A. fuscus on Ashmore Reef, 286 
where hybrid individuals closely resemble A. laevis in phenotype (Sanders et al., 2014). 287 
In similarity with the predominance of PLA2s over 3FTxs herein reported for A. laevis 288 
venom, a transcriptomic study on the venom glands of Aipysurus eydouxii revealed the 289 
existence of as many as sixteen unique PLA2 transcripts, in contrast to a single 290 
transcript corresponding to a 3FTx (Li et al., 2005). This could suggest that both 291 
Aipysurus species share the same venom compositional predominance. However, 292 
assessment of this possibility would require a direct examination of the A. eydouxii 293 
venom proteins, in addition to its venom gland transcripts. 294 
 Individual variations of toxin expression in snake venoms are not uncommon 295 
(Chippaux et al., 1991). To investigate the possible individual variability in A. laevis, 296 
samples from three specimens (“Mifisto”,  “Medusa”,  and  “Nessi”)  were compared by 297 
RP-HPLC (Fig.3). This analysis revealed that some qualitative variation in toxin 298 
expression was indeed present, although most fractions did not show significant 299 
deviation in abundance between specimens or pooled venom. 300 
Unlike several terrestrial elapids (Aird, 2002; Laustsen et al., 2015a), 301 
nucleosides were not detected in A. laevis venom. On the other hand, its high content of 302 
PLA2s suggests that this venom might induce myotoxicity, as previously shown in 303 
experimental studies (Zimmerman et al., 1992c; Ryan and Yong, 1997, 2002). Systemic 304 
myotoxicity, i.e. rhabdomyolysis, with myoglobinuria characterizes envenomings by 305 
some species of sea snakes in humans (Reid, 1961), and is responsible for acute kidney 306 
injury. However, when a pool of PLA2 fractions of A. laevis venom was tested for 307 
myotoxicity in mice, only a mild effect was observed, as judged by increments in 308 
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plasma CK activity. Mice receiving PBS had CK activity of 215 ± 10 U/L, and mice 309 
injected in the gastrocnemius, thigh, or soleus muscles with 30 µg of the PLA2 fraction 310 
pool had plasma CK activities of 926 ± 160 U/L, 1196 ± 119 U/L, and 764 ± 182 U/L 311 
(mean ± SEM), respectively. Increments in CK were significant only when the PLA2 312 
fraction pool was injected in the gastrocnemius and thigh muscles (p<0.05). Thus, A. 313 
laevis PLA2s only induced a mild myotoxic effect. In agreement, histological analysis of 314 
the soleus muscle 3 h after injection of PLA2 fraction pool showed only few scattered 315 
necrotic fibers (Fig.4). These observations contrast with the prominent increment in 316 
plasma CK activity described for other elapid venoms, such as that of Micrurus 317 
nigrocinctus (Fernández et al., 2011). By using native zone electrophoresis, it was 318 
observed that all PLA2 fractions (peaks 9-18) migrated towards the anode, indicating 319 
that they were of acidic nature (not shown). This observation could explain the low 320 
myotoxic effect of the PLA2 pool tested, since commonly PLA2s having potent 321 
myotoxic effects are of a basic nature (Montecucco et al., 2008). Our results suggest 322 
that myotoxicity is unlikely to be a significant effect in envenomings by A. laevis. 323 
 In agreement with its proteomic composition showing an abundance of PLA2s, 324 
high PLA2 activity of the venom was confirmed in vitro (Fig.5A), whereas no 325 
proteinase activity was detected (Fig.5B), in line with the absence of these enzymes in 326 
the venom proteome. Three-finger toxins were shown to represent the second major 327 
group of venom proteins in terms of abundance (25.3%), and all of them were identified 328 
as short neurotoxin isoforms (Table 1), previously characterized by Maeda and Tamiya 329 
(1976) and Ducancel et al. (1990). These short neurotoxins have been shown to bind 330 
with high affinity to nicotinic receptors at the motor end-plate of muscle fibers, leading 331 
to flaccid paralysis, which may result in respiratory failure and death (Maeda and 332 
Nobuo, 1976; Ducancel et al., 1990).  333 
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 All venom fractions were examined for acute toxicity in CD1 mice, and LD50 334 
values were determined for most of those having a Toxicity Score below 1 (Table 2). 335 
All fractions containing short neurotoxins (fractions 1-4) and some fractions containing 336 
PLA2s (fractions 5-18) induced lethality in mice, although the LD50 values of the short 337 
neurotoxins were 10-40 fold lower than those of the PLA2s. Evaluated on the basis of 338 
their Toxicity Score, the short neurotoxins of A. laevis venom are the most relevant 339 
toxins to target in order to counteract the main clinical manifestations of the venom. The 340 
venom of A. laevis is remarkably simple compared to terrestrial elapids, such as 341 
Dendroaspis polylepis (Laustsen et al., 2015a) and Naja kaouthia (Laustsen et al., 342 
2015b), which display a more diverse arsenal of toxins, although also being dominated 343 
by only two main toxin families. 344 
 The concept of a Toxicity Score for acute toxicity was presented for the first 345 
time in Laustsen et al. (2015a), and this score can be used to rank the importance of the 346 
individual toxins for acute toxicity in the given in vivo model (typically rodents). By 347 
examining the difference between the Toxicity Score of whole venom and the 348 
Accumulated Toxicity Score for all venom components (the sum of the Toxicity Scores 349 
for all the for the individual venom components), an indication of how the toxins in 350 
whole venom interact can be deduced. For a venom displaying synergism, the Toxicity 351 
Score for whole venom will be higher that the sum of the Toxicity Score for the 352 
individual components, since the synergistic effects between toxins will lead to an 353 
increased potency of the venom. For A. laevis there seems to be an indication that the 354 
Toxicity Score of whole venom (TS = 676) is almost the double of the Accumulated 355 
Toxicity Score of the venom components (ATS = 357) (Table 2), indicating that 356 
synergistic effects may exist. This observation is supported by previous studies 357 
indicating the presence of synergism (Ryan and Yong, 1997), which is quite fascinating 358 
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given the simplicity of this venom, being dominated by only a few very similar isoforms 359 
of short neurotoxins responsible for the main neurotoxic effects.   360 
 361 
3.2 Venom neutralization and antivenom profiling 362 
 The ability of BioCSL Sea Snake Antivenom and ICP Anti-Coral Antivenom to 363 
neutralize A. laevis venom was investigated in CD-1 mice. The BioCSL Sea Snake 364 
Antivenom was effective in neutralizing lethality with an ED50 of 821 Pg venom per mL 365 
antivenom (95% confidence limits: 478–1439 Pg/mL), whereas no neutralization was 366 
observed for ICP Anti-Coral Antivenom at a level of 100 Pg venom per mL. Our 367 
observations are in agreement with previous findings on the ability of BioCSLSea 368 
Snake Antivenom to neutralize the neuromuscular blocking activity of A. laevis and 369 
other sea snake venoms (Chetty et al., 2004). To further investigate the antivenoms, 370 
both BioCSL Sea Snake Antivenom and ICP Anti-Coral Antivenom were profiled by 371 
ELISA to determine the extent of binding between antivenom antibodies and toxins in 372 
A. laevis venom (Fig.6). Two general trends present themselves: BioCSL Sea Snake 373 
Antivenom displays significantly higher binding to fractions containing short 374 
neurotoxins (fractions 1-4), whereas the ICP Anti-Coral Antivenom displays either 375 
similar or even increased binding against PLA2 containing fractions (fractions 5-18). 376 
This finding further supports that the short neurotoxins are responsible for the main 377 
toxic effects of A. laevis venom.  378 
The underlying reason for the differences in binding preference between the two 379 
antivenoms may be explained by the venom compositions of Micrurus nigrocinctus and 380 
Enhydrina schistosa, which are used in the immunization mixtures of BioCSL Sea 381 
Snake Antivenom and ICP Anti-Coral Antivenom, respectively (Fig.7A). It must be 382 
noted, however, that it is not unlikely that horses hyper-immunized with several 383 
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different snake venoms were used for production of BioCSL Sea Snake Antivenom, and 384 
that  the  “monovalence”  of  this  antivenom  is  primarily  due  to  the  horses  being  boosted  385 
with E. schistosa venom immediately before bleeding (Chetty et al., 2004; O’Leary  and  386 
Isbister, 2009; Herrera et al., 2014). Therefore, unexpected cross-reactivity is not an 387 
unlikely event. E. schistosa venom has a high abundance of 3FTxs with a high degree of 388 
conservation relative to the short neurotoxins found in A. laevis (Fig.7B), and it is 389 
therefore not surprising that the BioCSL Sea Snake Antivenom has a strong preference 390 
for fractions 1-4, containing short neurotoxins from A. laevis. In comparison, the PLA2s 391 
found in M. nigrocinctus venom are not more similar to the PLA2s found in A. laevis 392 
venom than the PLA2 reported for E. schistosa venom (Fig.7C) (Fohlman and Eaker, 393 
1977). However, it is speculated that the much higher abundance of PLA2s in the 394 
immunization mixture used for producing ICP Anti-Coral Antivenom in itself drives the 395 
immunological response towards a stronger recognition against PLA2s in general. Given 396 
that BioCSL Sea Snake Antivenom readily cross-recognizes the neurotoxic components 397 
having the highest Toxicity Scores, and since this antivenom was shown to neutralize 398 
whole venom in rodents, BioCSL Sea Snake Antivenom should be useful for treating 399 
human snakebite accidents inflicted by A. laevis. 400 
 The venom of A. laevis is remarkably simple. It could therefore be feasible to 401 
develop modern antivenoms based on human(ized) monoclonal antibodies or peptide-402 
based inhibitors against this venom, since it is likely that only few antibodies are needed 403 
to obtain its full neutralization. The degree of conservation, especially in the clinically 404 
relevant short neurotoxins is high, and it is therefore likely that a potent, cross-reactive 405 
antibody or peptide-based inhibitor capable of neutralizing all of these components can 406 
be developed. 407 
 408 
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4.0 Concluding remarks and outlook 409 
 A proteomic analysis and functional study of A. laevis venom was carried out, 410 
revealing that this venom is remarkably simple and dominated by PLA2s (71.2% of 411 
venom protein content) followed by short neurotoxins of the three-finger toxin family 412 
(25.3% of venom protein content). Also, cysteine-rich secretory proteins (CRISP) and a 413 
complement control module (CCM) were detected. Based on thorough toxicity testing 414 
of the individual fractions obtained from whole venom, the most relevant toxins to 415 
target for an effective antivenom against acute toxicity are the short neurotoxins. Based 416 
on their Toxicity Scores, the toxins present in A. laevis venom seem to interact in a 417 
slightly synergistic manner, possibly due to the short neurotoxins all targeting the 418 
nicotinic receptors at the motor end-plate of muscle fibers. BioCSL Sea Snake 419 
Antivenom was capable of neutralizing A. laevis venom in CD-1 mice when venom and 420 
antivenom were preincubated and administered by i.v. injection. ELISA-based 421 
immunoprofiling indicated that the BioCSL Sea Snake Antivenom has a binding 422 
preference for short neurotoxins. Therefore, this antivenom should be of clinical use for 423 
treating bites inflicted by A. laevis. Finally, given the simplicity of A. laevis venom, a 424 
potential for developing a modern antivenom based on human(ized) monoclonal 425 
antibodies or peptide-based inhibitors may be a possibility in the future. 426 
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Figure legends 607 
 608 
Figure 1: Separation of A. laevis (A) venom proteins by RP-HPLC (C), followed by 609 
SDS-PAGE (B). Two mg of venom were fractionated on a C18 column and eluted with 610 
an acetonitrile gradient (dashed line), as described in Methods. Fractions were further 611 
separated by SDS-PAGE under reducing conditions. Molecular weight markers (Mw) 612 
are indicated in kDa. Coomassie-stained bands were excised, in-gel digested with 613 
trypsin, and subjected to MALDI-TOF/TOF analysis for assignment to protein families, 614 
as shown in Table 1. 615 
 616 
Figure 2: Composition of A. laevis venom according to protein families, expressed as 617 
percentages of the total protein content. 3FTx: three-finger toxin; PLA2: phospholipase 618 
A2; CRISP: cysteine-rich secretory protein; CCM: complement control module. (see 619 
Table 1). 620 
 621 
Figure 3: Comparison of the chromatographic profiles of the venoms from three 622 
individual A. laevis speciments  (“Mifisto”,  “Medusa”,  and  “Nessi”).  The patterns of the 623 
individual venoms are similar, although some differences do occur in abundance for 624 
certain fractions. Fraction peaks representing more than 1% of total venom protein, 625 
which have an abundance deviating more than 50% from the pool, are marked with *. 626 
 627 
Figure 4: Light micrographs of sections of mouse soleus muscles collected 3 h after 628 
injection of either phosphate-buffered saline (PBS) solution (A) or 30 µg of a pool of all 629 
the PLA2 fractions of the venom of A. laevis (B) (see Methods for experimental details). 630 
A normal histological pattern is observed in (A), whereas few scattered necrotic muscle 631 
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fibers (arrows) are observed in (B), thus evidencing the mild myotoxic activity of this 632 
venom. Hematoxylin-eosin staining. Bar represents 100 µm. 633 
 634 
Figure 5: (A) Comparison of the phospholipase A2 activity between the venoms of 635 
Aipysurus laevis, Dendroaspis polylepis, Naja kaouthia, and Micrurus nigrocinctus. A. 636 
laevis displays high enzymatic activity, although lower than M. nigrocinctus. (B) 637 
Comparison of the proteolytic activity between the venoms of A. laevis, D. polylepis, N. 638 
kaouthia, M. nigrocinctus, and Bpthrops asper, evaluated on azocasein. A. laevis shows 639 
negligible proteinase activity. 640 
 641 
Figure 6: ELISA-based immunoprofiling of antivenoms (CSL Sea Snake: BioCSL Sea 642 
Snake Antivenom from BioCSL Limited, ICP Micrurus: Monospecific Micrurus 643 
nigrocinctus Anticoral Antivenom from Instituto Clodomiro Picado, for comparison, 644 
and a negative control (Horse negative: normal serum from non-immunized horses 645 
from Instituto Clodomiro Picado) to all fractions of A. laevis venom separated by RP-646 
HPLC (see Methods for details). For identification of venom fractions refer to Table 2. 647 
Each bar represents mean ± SD of triplicate wells. 648 
 649 
Figure 7: (A) Comparison between the venom profiles and similarities of toxins from 650 
Aipysurus laevis, Enhydrina schistosa (Hydrophis schistosa), and Micrurus 651 
nigrocinctus. E. schistosa venom is used for production of BioCSL Sea Snake 652 
Antivenom, while M. nigrocinctus venom  is  used  for  production  of  ICP’s  Monospecific  653 
M. nigrocinctus Anticoral Antivenom. *Venom composition is based on venomics 654 
studies of M. nigrocinctus (Fernández et al., 2011) and the reported study of Hydrophis 655 
cyanocinctus (Calvete et al., 2012), as such studies have not been performed on E. 656 
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schistosa. Notice that the PLA2 content of the venoms differ. The green frames 657 
highlight observations used in discussion of Fig.6 (see text). (B) Alignment of all 658 
known three-finger toxins (3FTx) from A. laevis with the most similar toxins from M. 659 
nigrocinctus and E. schistosa. A high degree of conservation exists between short 660 
neurotoxins from A. laevis and the most similar E. schistosa toxin, possibly explaining 661 
the observed cross-reactivity of BioCSL Sea Snake Antivenom. (C) Alignment of the 662 
single known PLA2 from A. laevis with the most similar toxins from M. nigrocinctus 663 
and E. schistosa, showing only a limited degree of conservation. 664 
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Table 1: A
ssignm
ent of the R
P-H
PLC
 isolated fractions of Aipysurus laevis venom
 to protein fam
ilies by M
A
LD
I-TO
F-TO
F of selected 
peptide ions from
 in-gel trypsin-digested protein bands. 
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ass 
(kDa) ▼ 
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S-derived sequence * 
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(%
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Related protein, code  
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short neurotoxin 
Aipysurus laevis, P19960 
 
 
 
 
 
 
 
 
 
 
5a 
0.1 
29 
1758.8 
1895.8 
1774.8 
1 1 1 
N
X
Y
B
FD
N
M
X
B
C
A
N
K
 
A
H
D
D
C
Y
G
V
A
ED
(N
da)G
C
SPK
 
N
X
Y
B
FD
N
(M
ox)X
B
C
A
N
K
 
99 
99 
99 
10 
26 
11 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
C9  
 
 
 
 
 
 
 
 
 
 
 
5b 
0.3 
18 
1758.9 
1870.9 
2995.5 
2337.1 
1 1 1 1 
N
X
Y
B
FD
N
M
X
B
C
A
N
K
 
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
99 
99 
99 
99 
14 
14 
19 
19 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1  
 
 
31 
2091.0 
1 
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
99 
17 
 
 
 
 
 
 
 
 
 
 
6 
0.5 
18 
1758.9 
1870.9 
2994.5 
2337.1 
2091.0 
1 1 1 1 1 
N
X
Y
B
FD
N
M
X
B
C
A
N
K
 
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
99 
99 
99 
99 
99 
13 
17 
21 
19 
21 
PLA
2  
  
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1  
 
 
 
 
 
 
 
 
 
 
 
7 
0.2 
- 
- 
- 
- 
- 
- 
unknow
n 
- 
 
 
 
 
 
 
 
 
 
 
8 
0.4 
- 
- 
- 
- 
- 
- 
unknow
n 
- 
 
 
 
 
 
 
 
 
 
 
9 
9.6 
10 
2091.0 
1 
D
Y
G
C
Y
C
G
A
G
G
SG
TPV
D
A
X
D
R
 
99 
11 
PLA
2  
 
β-bungarotoxin chain A
2 
Bungarus caeruleus, ~Q
8Q
FW
3 
 
 
 
 
 
 
 
 
 
 
10 
6.2 
10 
2337.1 
2995.5 
1710.9 
2091.0 
1870.9 
1 1 1 1 1 
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
N
X
Y
B
FD
N
(M
dt)X
B
C
A
N
K
 
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
99 
99 
99 
99 
91 
11 
18 
14 
17 
9 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1  
 
 
 
 
 
 
 
 
 
 
11a 
3.1 
23 
1758.9 
1 
N
X
Y
B
FD
N
M
X
B
C
A
N
K
 
99 
14 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
11b 
9.1 
15 
2912.3 
1998.8 
2896.3 
1774.8 
1 1 1 1 
A
TW
H
Y
(M
ox)D
Y
G
C
Y
C
G
SG
G
SG
TPV
D
A
X
D
R
 
V
H
D
D
C
Y
G
V
A
ED
N
G
C
Y
PK
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
SG
G
SG
TPV
D
A
X
D
R
 
N
X
Y
B
FD
N
(M
ox)X
B
C
A
N
K
 
99 
98 
95.4 
67.2 
12 
8 8 7 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
D
8 
 
 
 
 
 
 
 
 
 
 
11c 
7.2 
10 
2091.0 
2895.4 
1710.9 
1 1 1 
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
SG
G
SG
TPV
D
A
X
D
R
 
N
X
Y
B
FD
N
(M
dt)X
B
C
A
N
K
 
99 
99 
99 
10 
14 
10 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
12a 
2.7 
15 
2896.3 
1774.8 
1 1 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
SG
G
SG
TPV
D
A
X
D
R
  
N
X
Y
B
FD
N
(M
ox)X
B
C
A
N
K
 
97.3 
95.3 
6 6 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
12b 
3.3 
10 
2835.4 
2896.4 
1213.6 
1758.9 
1894.8 
1 1 1 1 1 
W
TX
Y
SW
B
C
TEN
V
PTC
N
SESG
C
B
K
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
SG
G
SG
TPV
D
A
X
D
R
 
C
FA
EA
PY
N
N
K
 
N
X
Y
B
FD
N
M
X
B
C
A
N
K
 
A
H
D
D
C
Y
G
V
A
ED
N
G
C
SPK
 
99 
99 
99 
99 
99 
15 
23 
16 
18 
23 
PLA
2  
 
phospholipase A
2 
Aipysurus laevis, P08872 
  Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
13a 
1.7 
20 
1758.8 
1213.6 
2013.9 
1 1 1 
N
X
Y
B
FD
N
M
X
B
C
A
N
K
 
C
FA
EA
PY
N
N
K
 
A
H
D
D
C
Y
G
V
A
ED
N
G
C
Y
PK
 
99 
99 
99 
9 
12 
20 
PLA
2  
 
phospholipase A
2 
Aipysurus laevis, P08872 
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13b 
9.3 
10 
1758.9 
2994.5 
1870.9 
2337.1 
2091.0 
1 1 1 1 1 
N
X
Y
B
FD
N
M
X
B
C
A
N
K
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
99 
99 
99 
99 
99 
16 
22 
19 
24 
24 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
14a 
0.6 
20 
2970.3 
1352.5 
1 1 
A
TW
H
Y
TD
Y
G
C
Y
C
G
B
G
G
SG
TPV
D
EX
D
R
 
TH
D
D
C
Y
G
EA
EK
 
99 
99 
12 
17 
PLA
2  
 
phospholipase PLA
-2 
Notechis scutatus, ~Q
45Z32 
 
 
 
 
 
 
 
 
 
 
14b 
1.9 
10 
2994.4 
1 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
 
99 
14 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
15a 
0.2 
15 
1970.8 
1 
A
H
D
D
C
Y
G
V
A
ED
N
G
C
Y
PK
 
99 
17 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
15b 
0.1 
10 
1970.8 
2995.4 
1 1 
A
H
D
D
C
Y
G
V
A
ED
N
G
C
Y
PK
 
A
TW
H
Y
M
D
Y
G
C
Y
C
G
W
G
G
SG
TPV
D
A
X
D
R
 
99 
80 
19 
7 
PLA
2  
 
phospholipase A
2 
Aipysurus eydouxii, ~Q
5D
N
E1 
 
 
 
 
 
 
 
 
 
 
16a 
0.1 
15 
- 
- 
- 
- 
- 
unknow
n 
- 
 
 
 
 
 
 
 
 
 
 
16b 
0.1 
10 
2050.0 
1774.9 
1 1 
Y
G
C
Y
C
G
SG
G
SG
TPV
D
EX
D
R
 
N
X
Y
B
FD
N
(M
ox)X
B
C
A
N
K
 
99 
92.8 
12 
8 
PLA
2  
 
PLA
2 -D
en-12 
Denisonia devisi, ~R
4G
7G
2 
 
 
 
 
 
 
 
 
 
 
17 
3.6 
10 
2905.5 
2050.0 
1 1 
SV
W
D
FTN
Y
G
C
Y
C
G
SG
G
SG
TPV
D
EX
D
R
 
Y
G
C
Y
C
G
SG
G
SG
TPV
D
EX
D
R
 
99 
99 
16 
17 
PLA
2  
 
PLA
2 -9 
M
icrurus fulvius, ~U
3FY
N
8 
 
 
 
 
 
 
 
 
 
 
18 
11.6 
10 
2970.4 
1352.6 
1 1 
(S
pa)V
W
D
FTN
Y
G
C
Y
C
G
SG
G
SG
TPV
D
EX
D
R
 
(T
fo)H
D
D
C
Y
G
EA
EK
 
99 
99 
16 
21 
PLA
2  
 
PLA
2 -9 
M
icrurus fulvius, ~U
3FY
N
8 
 
 
 
 
 
 
 
 
 
 
19a.i 
0.4 
37 
1614.9 
1 
X
G
EEV
TX
G
C
N
Y
G
FR
 
99 
11 
C
C
M
 
com
plem
ent decay-accelerating factor 
transm
em
brane isoform
 
Ophiophagus hannah, ~V
8N
M
67  
 
 
 
 
 
 
 
 
 
 
19a.ii 
 
37 
1777.0 
1 
Y
X
Y
V
C
B
Y
CPA
G
N
X
R
 
99 
15 
C
R
ISP 
 
C
R
ISP 
Hydrophis hardwickii, ~A
A
L54918 
 
 
 
 
 
 
 
 
 
 
19b 
1.6 
20 
1161.5 
1719.8 
1 1 
Y
N
N
D
FSN
C
K
 
Y
X
Y
V
C
B
Y
CPA
G
N
X
R
 
99 
99 
10 
13 
C
R
ISP 
 
C
R
ISP-A
ca-1 
Acanthophis wellsi, ~R4FJD
0 
 
 
 
 
 
 
 
 
 
 
19c 
0.4 
15 
1776.8 
1 
Y
X
Y
V
C
B
Y
CPA
G
N
X
R
 
99 
20 
C
R
ISP 
 
C
R
ISP 
Hydrophis hardwickii, ~A
A
L54918 
 
 
 
 
 
 
 
 
 
 
19d 
0.3 
10 
1776.8 
1 
Y
X
Y
V
C
B
Y
CPA
G
N
X
R
 
99 
15 
C
R
ISP 
 
C
R
ISP 
Hydrophis hardwickii, ~A
A
L54918 
 
 
 
 
 
 
 
 
 
 
20 
0.1 
- 
- 
- 
- 
- 
- 
unknow
n 
- 
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* C
ysteine residues are carbam
idom
ethylated. C
onfidence (C
onf) and Score (Sc) values are calculated by the Paragon
® algorithm
 of 
ProteinPilot ®.  ▼
:  reduced SD
S-PA
G
E m
ass estim
ations, in kD
a. X
: Leu/Ile; B
: Lys/G
ln; Z: pyroglutam
ate (2-oxo-pyrrolidone 
carboxylic acid). Possible, although unconfirm
ed/am
biguous am
ino acid m
odifications suggested by the autom
ated identification 
softw
are are show
n in parentheses, w
ith the follow
ing abbreviations: ox: oxidized; da: deam
idated; dt: dethiom
ethyl; pa: propionam
ide; fo: 
form
ylated. 
** Protein fam
ily abbreviations: 3FTx: three-finger toxin; PLA
2 : phospholipase A
2 ; C
R
ISP: cysteine-rich secretory protein; C
C
M
: 
com
plem
ent control m
odule. 
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Table 2: LD
50  values of Aipysurus laevis venom
 and the R
P-H
PLC
 isolated fractions 
 
Peak 
%
 
Protein family 
LD
50 
(95%
 C.L.) 
Toxicity Score 1 
%
 / LD
50 
(kg/mg) 
W
hole venom
 
100 
 
0.15 
(0.08-0.25) 
676 
1 
21.8 
3FTx: short neurotoxin 
0.07 
(0.04-0.15) 
334 
2 
0.6 
3FTx: short neurotoxin 
0.18 
(0.01-0.69) 
3.3 
3 
2.0 
3FTx: short neurotoxin 
0.13 
(0.09-0.44) 
15.3 
4 
0.9 
3FTx: short neurotoxin 
0.28 
(0.14-0.99) 
3.2 
5 
0.3 
PLA
2 : Phospholipase A
2 
>0.3 
<1 
6 
0.5 
PLA
2 : Phospholipase A
2 
>0.5 
<1 
7 
0.2 
U
nknow
n 
>0.25 
<1 
8 
0.4 
U
nknow
n 
>0.5 
<1 
9 
9.6 
PLA
2 : Phospholipase A
2 
>10 
<1 
10 
6.3 
PLA
2 : Phospholipase A
2  
>7.5 
<1 
11 
19.4 
PLA
2 : Phospholipase A
2  
>20 
<1 
12 
6.0 
PLA
2 : Phospholipase A
2  
>6 
<1 
 
35 
13 
11.0 
PLA
2 : Phospholipase A
2  
>10 
<1.1 
14 
2.5 
PLA
2 : Phospholipase A
2  
>2.5 
<1 
15 
0.3 
PLA
2 : Phospholipase A
2  
>0.3 
<1 
16 
0.2 
PLA
2 : Phospholipase A
2  
>0.25 
<1 
17 
3.6 
PLA
2 : Phospholipase A
2  
3.05 
(1.92-4.67) 
1.2 
18 
11.6 
C
C
M
 
>>2.5 
<5 
19 
2.7 
C
R
ISP 
>0.5 
<1 
20 
0.1 
C
R
ISP 
N
.t. 
N
.t. 
 *http://snakedatabase.org/pages/LD
50.php#legendA
ndD
efinitions  
1Toxicity Score w
as defined as the ratio of protein fraction abundance (%
) in the venom
 divided by 
its estim
ated m
edian lethal dose (LD
50 ) for C
D
-1 m
ice by i.v. injection. 
2M
ix indicates that the fraction did not contain a pure, isolated toxin, but instead a m
ixture of 2-4 
different toxins in variable ratios indicted in the table. 
 N
.t. : not tested 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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